Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

PHASE3CompletedINTERVENTIONAL
Enrollment

938

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions
Pneumococcal Infections
Interventions
BIOLOGICAL

13 valent Pneumococcal Conjugate Vaccine

0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1

BIOLOGICAL

23vPS

0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1

Trial Locations (58)

14642

Pfizer Investigational Site, Rochester

15106

Pfizer Investigational Site, Carnegie

15241

Pfizer Investigational Site, Pittsburgh

Pfizer Investigational Site, Upper Saint Clair

16127

Pfizer Investigational Site, Grove City

19047

Pfizer Investigational Site, Penndel

19335

Pfizer Investigational Site, Downington

21120

Pfizer Investigational Site, Malmo

21209

Pfizer Investigational Site, Baltimore

23234

Pfizer Investigational Site, Arlöv

23507

Pfizer Investigational Site, Norfolk

27103

Pfizer Investigational Site, Winston-Salem

27511

Pfizer Investigational Site, Cary

27612

Pfizer Investigational Site, Raleigh

27705

Pfizer Investigational Site, Durham

27710

Pfizer Investigational Site, Durham

28144

Pfizer Investigational Site, Salisbury

28209

Pfizer Investigational Site, Charlotte

28601

Pfizer Investigational Site, Hickory

29464

Pfizer Investigational Site, Mt. Pleasant

29651

Pfizer Investigational Site, Greer

29731

Pfizer Investigational Site, Degeberga

30305

Pfizer Investigational Site, Atlanta

30328

Pfizer Investigational Site, Atlanta

Pfizer Investigational Site, Stockbridge

32216

Pfizer Investigational Site, Jacksonville

33134

Pfizer Investigational Site, Coral Gables

33614

Pfizer Investigational Site, Tampa

33761

Pfizer Investigational Site, Clearwater

33781

Pfizer Investigational Site, Pinellas Park

36608

Pfizer Investigational Site, Mobile

37232

Pfizer Investigational Site, Nashville

37620

Pfizer Investigational Site, Bristol

40014

Pfizer Investigational Site, Gothenburg

40536

Pfizer Investigational Site, Lexington

44195

Pfizer Investigational Site, Cleveland

45229

Pfizer Investigational Site, Cincinnati

45236

Pfizer Investigational Site, Cincinnati

55417

Pfizer Investigational Site, Minneapolis

55905

Pfizer Investigational Site, Rochester

58103

Pfizer Investigational Site, Fargo

59701

Pfizer Investigational Site, Butte

63104

Pfizer Investigational Site, St Louis

63141

Pfizer Investigational Site, St Louis

66128

Pfizer Investigational Site, Shawnee Mission

75185

Pfizer Investigational Site, Uppsala

78705

Pfizer Investigational Site, Austin

80262

Pfizer Investigational Site, Denver

85203

Pfizer Investigational Site, Mesa

85213

Pfizer Investigational Site, Mesa

89146

Pfizer Investigational Site, Las Vegas

90736

Pfizer Investigational Site, Umeå

92708

Pfizer Investigational Site, Fountain Valley

96131

Pfizer Investigational Site, Boden

97330

Pfizer Investigational Site, Corvallis

97401

Pfizer Investigational Site, Eugene

998101

Pfizer Investigational Site, Seattle

06708

Pfizer Investigational Site, Waterbury

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00546572 - Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) | Biotech Hunter | Biotech Hunter